ProKidney Corp.
corporate_fare Company Profile
ProKidney Corp. (NASDAQ:PROK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for PROK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for PROK spans 10-Q, 8-K, S-3, 10-K.
Recent high-impact activity:
- ProKidney 10-Q: $141.9M Cash Won't Fund 12 Months, Going Concern Doubt
- Q3 Loss Widens to $51.8M as Cash Drops $39.7M; PROACT 1 Readout Set for Q2 2027
- ProKidney Discloses $141.9M Cash, Runway Into Mid-2027, and Lifted PROACT 1 Enrollment Target
- ProKidney Files $650M Shelf and $200M Jefferies ATM Weeks After Going-Concern Warning
- ProKidney Q2 Loss Widens to $48M as Trial Costs Surge; Enrollment Milestone Hit
Financial Snapshot
Short Interest & Short Volume
22.51 days to coverFINRA reported short interest of 24,336,295 shares in PROK as of the October 30, 2026 settlement, a 0.9% decrease from the prior period — about 22.5 days to cover at its recent average daily volume. On November 20, 2026, 73.0% of PROK volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for PROK, detected from its recent SEC filings · based on capital-structure filings through 2026-11-12.
ATM Prospectus Supplement Filed · No Shares Sold Yet
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →